Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial ribosomal protein S22 (MRPS22) is a nuclear-encoded protein that forms part of the small (28S) subunit of the mitochondrial ribosome, essential for the assembly and stability of 12S rRNA. It plays a crucial role in mitochondrial protein synthesis, which is required to produce polypeptides that are components of the mitochondrial respiratory chain complexes (except complex II). Disruption of MRPS22 function, such as by deleterious mutations, leads to impaired assembly of the mitochondrial small ribosomal subunit, decreased 12S rRNA levels, and defective mitochondrial translation, resulting in combined oxidative phosphorylation deficiencies. MRPS22 is also implicated in tissue-specific processes such as ovarian development: biallelic pathogenic variants in MRPS22 can cause primary ovarian insufficiency and ovarian dysgenesis. Despite its essential molecular role, MRPS22 is not considered a classical therapeutic target (such as a receptor, enzyme, or transporter)[1][2][3][4][5][6][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial ribosomal protein S22 (MRPS22).